Chung, V., Guthrie, K. A., Pishvaian, M. J., Lowy, A. M., Sohal, D., Reiss, K. A., Sanford, N. N., Allegra, C., Colby, S., O'Reilly, E. M., Chiorean, E. G., Philip, P. A. (2025). Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.tps793